| MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition G Mollaoglu, MR Guthrie, S Böhm, J Brägelmann, I Can, PM Ballieu, ... Cancer cell 31 (2), 270-285, 2017 | 463 | 2017 |
| MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate AS Ireland, AM Micinski, DW Kastner, B Guo, SJ Wait, KB Spainhower, ... Cancer cell 38 (1), 60-78. e12, 2020 | 295 | 2020 |
| Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer CA Stewart, CM Gay, Y Xi, S Sivajothi, V Sivakamasundari, J Fujimoto, ... Nature cancer 1 (4), 423-436, 2020 | 263 | 2020 |
| Inosine monophosphate dehydrogenase dependence in a subset of small cell lung cancers F Huang, M Ni, MD Chalishazar, KE Huffman, J Kim, L Cai, X Shi, F Cai, ... Cell metabolism 28 (3), 369-382. e5, 2018 | 158 | 2018 |
| MYC-driven small-cell lung cancer is metabolically distinct and vulnerable to arginine depletion MD Chalishazar, SJ Wait, F Huang, AS Ireland, A Mukhopadhyay, Y Lee, ... Clinical Cancer Research 25 (16), 5107-5121, 2019 | 138 | 2019 |
| MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer MA Dammert, J Brägelmann, RR Olsen, S Böhm, N Monhasery, ... Nature communications 10 (1), 3485, 2019 | 64 | 2019 |
| Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer F Huang, KE Huffman, Z Wang, X Wang, K Li, F Cai, C Yang, L Cai, ... The Journal of clinical investigation 131 (1), 2021 | 35 | 2021 |
| Sustained intratumoral activation of MM-398 results in superior activity over irinotecan demonstrated by using a systems pharmacology approach J Kim, E Bayever, P Laivins, C Niyikiza, U Nielsen, J Fitzgerald, A Kalra, ... Poster presented at the AACR Pancreatic Cancer Symposium, 2012 | 15 | 2012 |
| Evaluating determinants for enhanced activity of MM-398/PEP02; a novel nanotherapeutic encapsulation of irinotecan (CPT-11) A Kalra, S Klinz, N Paz, J Kim, M Chalishazar, D Drummond, D Kirpotin, ... Cancer Research 72 (8_Supplement), 5696-5696, 2012 | 9 | 2012 |
| Abstract A6: Sustained intratumoral activation of MM-398 results in superior activity over irinotecan demonstrated by using a systems pharmacology approach J Kim, E Bayever, P Laivins, C Niyikiza, U Nielsen, J Fitzgerald, A Kalra, ... Cancer Research 72 (13_Supplement), A6-A6, 2012 | 7 | 2012 |
| Abstract A63: MM-398/PEP02, a novel liposomal formulation of irinotecan, demonstrates stromal-modifying anticancer properties. N Paz, P Laivins, C Niyikiza, U Nielsen, J Fitzgerald, A Kalra, ... Cancer Research 72 (14_Supplement), A63-A63, 2012 | 2 | 2012 |
| Development of a bioluminescence reporter mouse model for tracking and quantifying Ly6G+ neutrophils in vivo MD Chalishazar, N Solban, J Kopinja, D Linn, R Cristescu, H Zhou, ... Cancer Research 82 (12_Supplement), 2455-2455, 2022 | | 2022 |
| Abstract PO-120: MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate AS Ireland, AM Micinski, DW Kastner, B Guo, SJ Wait, KB Spainhower, ... Cancer Research 80 (21_Supplement), PO-120-PO-120, 2020 | | 2020 |
| A08 MYC-Driven SCLC Has Unique Metabolic Vulnerabilities SJ Wait, MD Chalishazar, F Huang, JS Bomalaski, RJ DeBerardinis, ... Journal of Thoracic Oncology 15 (2), S14, 2020 | | 2020 |
| Metabolic Vulnerabilities in MYC-Driven Small Cell Lung Cancer MD Chalishazar The University of Utah, 2019 | | 2019 |
| MS32. 01 Genetic Mouse Models (GEMMS) G Mollaoglu, M Chalishazar, F Huang, M Guthrie, S Bohm, T Sen, L Byers, ... Journal of Thoracic Oncology 13 (10), S307-S308, 2018 | | 2018 |
| Abstract IA27: MYC drives molecular and therapeutically distinct subtype of SCLC G Mollaoglu, MR Guthrie, S Bohm, J Bragelmann, MD Chalishazar, ... Clinical Cancer Research 24 (17_Supplement), IA27-IA27, 2018 | | 2018 |
| Abstract A41: Sustained intratumoral activation of MM-398 results in superior activity over irinotecan demonstrated by using a systems pharmacology approach. J Kim, E Bayever, P Laivins, C Niyikiza, U Nielsen, J Fitzgerald, A Kalra, ... Cancer Research 72 (14_Supplement), A41-A41, 2012 | | 2012 |
